To assess the prognostic significance of mediastinal involvement of Hodgkin's disease, 91 patients with stage I to III disease treated at our Institute were reclassified according to size of mediastinal disease and other clinical and therapeutic characteristics. Complete remission (CR) was achieved in 46 of 67 (81%) patients without mediastinal involvement, and in 16 of 17 (94%) patients with small mediastinal masses, but only in 10 of 17 (59%) patients with large masses (P < 0.05). Twenty-seven of 32 (84%) patients treated with irradiation alone and 26 of 28 (93%) patients treated with combined modality therapy reached a CR, whereas such a result was obtained only in 19 of 31 (61%) patients who received MOPP chemotherapy alone (P < 0.01). In particular, none of the patients with large masses had a CR when treated with chemotherapy alone, whereas no differences in response to therapy were found between patients with large vs. small or no masses when irradiation or combined treatments were utilized. Since combined treatment seems to reach a high proportion of CR and to prevent extranodal relapse, further randomized clinical trials are needed to decide its routine utilization in patients with poor prognostic factors such as large mediastinal adenopathies.
Get full access to this article
View all access options for this article.
References
1.
BonadonnaG., SantoroA., ZucaliR., ValagussaP.: Improved five-year survival in advanced Hodgkin's disease by combined modality approach.Cancer Clin. Trials, 2: 82–89, 1979.
2.
CarboneP.P., KaplanH.S., MusshoffK., SmithersD.W., TubianaM.: Report of the Committee on Hodgkin's Disease Staging Classification.Cancer Res., 31: 1860–1861, 1971.
3.
CarmelR.J., KaplanH.S.: Mantle irradiation in Hodgkin's disease: An analysis of technique, tumor eradication, and complications.Cancer, 37: 2813–2825, 1976.
4.
CaseD.C., YoungC.W., LeeB.J.: Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine, and vinblastine (ABVD).Cancer, 39: 1382–1386, 1977.
5.
ColtmanC.A., FullerL.M., FisherR., FreiE.: Extended field radiotherapy plus MOPP in stage I and II Hodgkin's disease. In: Adjuvant Therapy of Cancer.JonesS.E., SalmonS.E. eds., pp. 129–136, New York, Grune and Stratton, 1979.
6.
CorneliaP., PetrulioF., ApiceG., SilvestroP., CorneliaG., ZarrilliD.: Utilità e limiti della laparoscopia nella definizione di stadio della malattia di Hodgkin.Prog. Med., 37: 204–208, 1981.
7.
CorneliaP., ScoppaG., VillariP., AbateG., CorneliaG., PergolaM., ZarrilliD.: Superiorità di un trattamento combinato radio-chemioterapico nel III stadio della malattia di Hodgkin con sintomi sistemici e/o localizzazione splenica.Med. Oggi, 1: 41–51, 1981.
8.
De VitaV.T., SerpickA.A., CarboneP.P.: Combination chemotherapy in the treatment of advanced Hodgkin's disease.Ann. Intern. Med., 73: 881–895, 1970.
9.
FullerL.M., Madoc-JonesH., GambleJ.F., ButlerJ.J., SullivanM.P., FernadezC.H., GehanE.A.: New assessment of the prognostic significance of histopathology in Hodgkin's disease for laparotomy-negative stage I and stage II patients.Cancer, 39: 2174–2182, 1977.
10.
FullerL.M., GambleJ.F., IbrahimE., JingB., ButlerJ.J., ShullenbergerC.C.: Stage II Hodgkin's disease: Significance of mediastinal and non-mediastinal presentations.Radiology, 109: 429–436, 1973.
KellerA.R., CastlemanR.: Hodgkin's disease of the thymus gland.Cancer, 33: 1615–1623, 1974.
17.
LeeC.K., BloomfieldC.D., GoldmanA.I., LevittS.H.: Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy.Cancer, 46: 2403–2409, 1980.
18.
LokichJ.J., FreiE.III, TaffeN., TullisJ.: New multiple agent chemotherapy (B-DOPA) for advanced Hodgkin's disease.Cancer, 38: 667–671, 1976.
19.
LukesR.J., CraverL.F., HallT.C., RappaportH., RubinP.: Report of the Nomenclature Committee.Cancer Res., 26: 1311, 1966.
20.
MauchP., GoodmanR., HellmanS.: The significance of mediastinal involvement in early stage Hodgkin's disease.Cancer, 42: 1039–1045, 1978.
21.
MazzaP., FiacchiniM., LauriaF., TuraS.: Uso della chemioterapia MOPP prima della radioterapia in pazienti in I e II stadio con grande impegno mediastinico.XXVIII Congresso Nazionale S.I.E. (Abstract), pag. 260, 1981.
22.
NissenN.I., NordentoftA.M., BrinckerH., AndersonE., Krogh JensenM., Boye NielsenJ., Pedersen-BjergaardJ., Skov JensenT., Bjørn JensenK., VidebaA.A., PedersenM., Walbom-JorgensenS.: Radioteharpy versus radiotherapy plus chemotherapy in stages I and II Hodgkin's disease.Scand. J. Haematol., 25: 35–44, 1980.
23.
PeneF., Henry-AmarM., Le BourgeoisJ.P., HayatM., Gérard-MarchantR., LaugierA., MathéG., TubianaM.: A study of relapse and course of 153 cases of Hodgkin's disease (clinical stages I and II) treated at the Institute Gustave-Roussy from 1963 to 1970 with radiotherapy alone or with adjuvant monochemotherapy.Cancer, 46: 2131–2141, 1980.
24.
PetoR., PikeM.C., ArmitageP., BreslowN.E., CoxD.R., HowardS.V., MantelN., McPhersonK., PetoT., SmithG.P.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient.2. Analysis and examples. Br. J. Cancer, 35: 1–39, 1977.
25.
PorzigK.J., PortlockC.S., RobertsonA., RosembergS.A.: Treatment of advanced Hodgkin's disease with B-CAVe following MOPP failure.Cancer, 41: 1670–1675, 1978.
26.
RodgersR.W., GambleJ.F., LohK.K., ShullenbergerC.C.: Adriamycin, bleomycin, DIC, CCNU and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.Cancer, 46: 2349–2355, 1980.
27.
SantoroA., BonadonnaG.: Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).Cancer Chemother. Pharmacol., 2: 101–105, 1979.
28.
TharT.L., MillionR.R., HausnerR.J., McKettyH.B.: Hodgkin's disease stage I and II: Relationship of recurrence to size of disease, radiation dose, and number of sites involved.Cancer, 43: 1101–1105, 1979.
29.
TubianaM.: The place of radiotherapy in the treatment of malignant lymphoma.Clin. Haematol., 3: 161–193, 1974.
30.
TubianaM., Henry-AmarM., HayatM., BreurK., Van Der Were-MessingB., BurgersM.: Long-term results of the E.O.R.T.C.randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease. Eur. J. Cancer, 15: 645–657, 1979.
31.
VinciguerraV., ColemanM., JarowskiC.I., DegnanI.V., SilverR.T.: A new combination chemotherapy for resistant Hodgkin's disease.J.A.M.A., 237: 33–35, 1977.
32.
ZucaliR., SantoroA., BonadonnaG.: Stage IIB Hodgkin's disease: Patterns of presentation and therapeutic results after combined chemotherapy-radiotherapy approach. UICC Conference on Clinical Oncology, Abstract 09-0464, 1981.
